Barclays lowers agilon health stock price target to $1.50 on EBITDA miss

Agilon Health (AGL) reported significantly disappointing Q2 results, missing revenue by $75 million, medical margin by $111 million, and EBITDA by $55 million, leading to the withdrawal of its full-year 2025 guidance. This poor performance prompted Barclays to halve its price target to $1.50 and BofA to reduce theirs to $1.30, both maintaining negative ratings. Concurrently, CEO Steven Sell stepped down, with co-founder Ronald Williams assuming interim leadership, highlighting broader visibility challenges in capitated provider models within the managed care sector.

Analysis

Agilon Health (AGL) is facing a significant operational and leadership crisis following a severe second-quarter 2025 performance miss. The company pre-announced results that fell short of expectations across key metrics, with a revenue miss of $75 million, a medical margin shortfall of $111 million, and an EBITDA miss of $55 million. This poor performance, which follows a 71% stock decline over the past year, prompted management to withdraw its full-year 2025 guidance, introducing substantial uncertainty into the company's financial outlook. Concurrently, the firm announced the immediate departure of CEO Steven Sell, a major governance flag. In response, both Barclays and BofA Securities have reinforced their negative stances, with Barclays cutting its price target by 50% to $1.50 and BofA lowering its target to $1.30. Barclays' commentary frames this as part of a broader negative trend in managed care, highlighting a systemic "lack of visibility into claims and risk adjustment for capitated provider models," which suggests Agilon's problems may reflect wider industry headwinds. The negative outlook is further substantiated by data indicating negative gross profit margins and eight downward analyst revisions for the upcoming period.

Key Decisions for Investors

• The combination of a severe earnings miss, withdrawn guidance, and an abrupt CEO departure signals profound operational distress, warranting extreme caution for any existing or potential long positions.
• Investors should treat the 71% year-over-year stock decline as a potential value trap rather than a buying opportunity, given the deteriorating fundamentals, negative gross profit margins, and lack of forward-looking visibility.
• The issues with claims visibility in Agilon's capitated provider model serve as a negative read-through for peers in the managed care sector utilizing similar risk-adjustment structures.
• A catalyst for re-evaluation would be the appointment of a permanent CEO with a credible turnaround strategy and the reinstatement of financial guidance, without which fundamental valuation is highly speculative.